- Home
- DSL vs AUPH Comparison
DSL vs AUPH Comparison
Compare DSL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSL | AUPH |
|---|---|---|
| Founded | 2013 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | DSL | AUPH |
|---|---|---|
| Price | $11.30 | $15.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 838.4K | ★ 1.0M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 11.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | N/A | ★ $265,808,000.00 |
| Revenue This Year | N/A | $21.76 |
| Revenue Next Year | N/A | $16.45 |
| P/E Ratio | ★ N/A | $27.87 |
| Revenue Growth | N/A | ★ 20.62 |
| 52 Week Low | $10.58 | $6.55 |
| 52 Week High | $12.92 | $16.54 |
Technical Indicators
Market Signals| Indicator | DSL | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 49.40 | 45.87 |
| Support Level | $11.22 | $15.15 |
| Resistance Level | $11.33 | $16.19 |
| Average True Range (ATR) | 0.07 | 0.47 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 77.50 | 29.65 |
Price Performance
Historical ComparisonAbout DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.